Evidence map›Paper›PMID 31324596›Full record

ArticleThe Lancet. Child & adolescent health2019

Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study.

Kendra K Radtke, Kelly E Dooley, Peter J Dodd, Anthony J Garcia-Prats, Lindsay McKenna, Anneke C Hesseling, Radojka M Savic

Open access · bronzeAbstract read
In one paragraph

Article in The Lancet. Child & adolescent health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Adequacy of WHO weight-band dosing and fixed-dose combinations for the treatment of TB in children.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  15. Tuberculosis in children with severe acute malnutrition.Expert review of respiratory medicine · 2022
    Review
  16. Is a high dose sufficient to achieve high isoniazid exposure in children affected by multidrug-resistant TB?The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2021
    Article
  17. Review
  18. Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian children.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2021
    Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Kendra K RadtkeDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Kelly E DooleyDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Peter J DoddSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
Anthony J Garcia-PratsDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Lindsay McKennaTreatment Action Group, HIV/TB Project, New York, NY, USA.
Anneke C HesselingDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Radojka M SavicDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA. Electronic address: rada.savic@ucsf.edu.
Desmond Tutu HIV Foundation · ZAUniversity of California, San Francisco · USJohns Hopkins University · USTreatment Action Group · USUniversity of Sheffield · GB

Funding

CLINICAL, PHARMACOLOGY, DRUG ACTION &PHARMACOKINETICST32GM007546 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Radojka Savic · 1985 to 2026
$8.9M
PHARMACEUTICAL SCIENCES AND PHARMACOGENOMICST32GM007175 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, KROETZ, DEANNA L · 1985 to 2021
$7.1M
Optimizing and operationalizing pediatric drug-resistant tuberculosis treatmentR01HD083047 · NICHD · STELLENBOSCH UNIVERSITY · PI GARCIA-PRATS, ANTHONY JOSEPH, SAVIC, RADOJKA · 2015 to 2019
$1.6M
Medical Research Council MR/P022081/1NICHD NIH HHS R01 HD083047NIGMS NIH HHS T32 GM007175NIGMS NIH HHS T32 GM007546
6 · The paper itself

Abstract

backgroundMalnourished and young children are particularly susceptible to severe forms of tuberculosis and poor treatment response. WHO dosing guidelines for drugs for tuberculosis treatment are based only on weight, which might lead to systematic underdosing and poor outcomes in these children. We aimed to assess and quantify the population effect of WHO guidelines for drug-susceptible tuberculosis in children in the 20 countries with the highest disease burden.

methodsWe used an integrated model that linked country-specific demographic data at the individual level from the 20 countries with the highest disease burden to pharmacokinetic, outcome, and epidemiological models. We estimated tuberculosis treatment outcomes in children younger than 5 years following WHO guidelines (children are dosed by weight bands corresponding to the number of fixed-dose combination tablets [75 mg rifampicin, 50 mg isoniazid, 150 mg pyrazinamide]) and two alternative dosing strategies: one based on a proposed algorithm that uses age, weight, and available formulations, in which underweight children would receive the same drug doses as would normal weight children of the same age; and another based on an individualised algorithm without dose limitations, in which derived doses results in target exposure attainment for the typical child.

findingsWe estimated that 57 234 (43%) of 133 302 children younger than 5 years who were treated for tuberculosis in 2017 were underdosed with WHO dosing and only 47% of children would reach the rifampicin exposure target. Underdosing and subtherapeutic exposures were more common among malnourished children than among age-matched healthy children. The proposed dosing approach improved estimated rifampicin target exposure attainment to 62% and equalised outcomes by nutritional status. An estimated third of unfavourable treatment outcomes might be resolved with this dosing strategy, saving the lives of a minimum of 2423 children in these countries annually. With individualised dosing approaches, almost all children could achieve adequate exposure for cure.

interpretationThis work shows that a simple change in dosing procedure to include age and nutritional status, requiring no additional measurements or new drug formulations, is one approach to improve tuberculosis treatment outcomes in children, especially malnourished children who are at high risk of mortality.

fundingEunice Kennedy Shriver National Institute of Child Health and Human Development and UK Medical Research Council.

Indexed as

Models, StatisticalAlgorithmsAntitubercular AgentsBody WeightChild Nutrition DisordersChild, PreschoolDrug Administration ScheduleHumansIsoniazidPractice Guidelines as TopicPyrazinamideRifampinTreatment OutcomeTuberculosisAntitubercular AgentsIsoniazidPyrazinamideRifampin

Identifiers

PMID31324596
PMCPMC7605863
OpenAlexW2961279458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.